News

Pfizer (NYSE: PFE) ended 2022 with a bang, delivering its highest level of revenue ever -- $100 billion -- thanks to its coronavirus vaccine and treatment. But the drop in demand for those products

Many stocks performed well last year, but Medtronic (NYSE: MDT) wasn't one of them. The medical device giant failed to keep pace with broader equities, partly because it was still dealing with

With CRISPR Therapeutics (NASDAQ: CRSP) in the news thanks to its successful work in developing cutting-edge gene therapies, it's easy to assume that everything in the business is going swimmingly

On Jan. 8, pharmaceutical giant Merck (NYSE: MRK) moved to acquire biotech Harpoon Therapeutics, (NASDAQ: HARP) for $680 million in cash. The point of the acquisition, which should close in the

Every portfolio should include a few monster stocks, or companies with huge market share and staying power, and products likely to drive growth for the long term. Healthcare is a great place to look

Sarepta Therapeutics (NASDAQ: SRPT) saw a lot of love from the market as the trading week kicked off on Monday. Investors pushed the stock almost 5% higher in price, a move due in no small part to

Vertex Pharmaceuticals (NASDAQ: VRTX) has been one of the fastest-growing healthcare companies in recent years. Its products have made it a leader in cystic fibrosis (CF) treatment and it has been

The new year is here, and for many, it's a fresh opportunity to set financial goals and find fresh stocks to consider adding to a portfolio. The types of stocks you gravitate toward will broadly be

Right now marks an exciting moment for CRISPR Therapeutics (NASDAQ: CRSP) and its investors. The biotech company has reached three milestones in just a couple of months. First, back in November, the

The healthcare sector is home to many excellent, innovative corporations that have made many investors richer. However, no healthcare company has reached a market capitalization of $1 trillion

COVID-19 has been especially rough for Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) investors over the last couple of years. Shares of both drugmakers have plunged as the demand for their

Shares of Humana (NYSE: HUM) fell as much as 12.8% on Thursday after the health insurance company cut its 2023 guidance, citing rising Medicare Advantage costs amid "higher than anticipated

While the market bounced back last year, some stocks failed to keep pace with broader equities. That was the case with pharma giant AbbVie (NYSE: ABBV) and e-commerce specialist Etsy (NASDAQ: ETSY)

It's hard for me to pick my top favorite in many categories. Whether talking about actors, athletes, songs, singers, movies, or TV shows, I find it difficult to single one out as the best.

This

In this video, I will go over four healthcare stocks that represent different exposures to the healthcare industry. One of the companies I cover happens to be the fifth-largest player in the

Abbott Laboratories (NYSE: ABT) and AbbVie (NYSE: ABBV) share a common past. About a decade ago, Abbott spun out its pharmaceuticals business into a separate company to create AbbVie. Since then

One of the most important companies during the peak of the COVID-19 pandemic was pharmaceutical giant Pfizer (NYSE: PFE). The company's breakthrough vaccine helped pave the way for a post-pandemic

For all of its many successes, the healthcare industry isn't exactly a hotbed of dividend-paying stocks. However, this doesn't mean the sector is entirely without companies that remunerate their

It's been a few years since the average investor behaved as if no challenge was too tough for America's biopharmaceutical industry. In turn, shares of gene-editing startup Editas Medicine (NASDAQ:

If you're in the process of rebalancing your portfolio, you might be considering buying Pfizer (NYSE: PFE) stock. After all, the drugmaker pays a sizzling 5.92% dividend yield, its shares trade at

Last year, pharmaceutical giant Pfizer (NYSE: PFE) encountered several issues, none more significant than the massive drop in revenue and earnings it experienced due to a shrinking coronavirus

There's no guarantee that any stock is completely unstoppable. However, three Motley Fool contributors think they've identified some that come close. Here's why they picked Eli Lilly (NYSE: LLY)

Last year wasn't a particularly good one for Pfizer (NYSE: PFE). Even CEO Albert Bourla says so. "We missed our internal projections and also, we missed the expectations of The Street... And

Clinical-stage biotech Vera Therapeutics (NASDAQ: VERA) had a week to remember on the stock market. Over the past five trading days, according to data compiled by S&P Global Market Intelligence, the

While investors love when one of their companies beats analyst estimates, it's not always the case that its stock rises in reaction. That was the case Friday with big health insurance company